British-Swedish pharmaceutical giant AstraZeneca has said it plans to build a $1.5 billion manufacturing facility in Singapore for antibody drug conjugates ADCs, to help enhance the global supply of its ADC portfolio, according to a May 20 media release.
ADCs are next-generation treatments that deliver cancer-killing agents directly to cancer cells through a targeted antibody. The manufacturing of ADCs includes antibody production the synthesis of chemotherapy drug and linker the conjugation of drug-linker to the antibody and the filling of the completed ADC substance.
AstraZeneca said that it aims to begin design and construction of the manufacturing facility by the...
¬ Haymarket Media Limited. All rights reserved.
